HBV Cure vignet
Meeting category
Date(s)
11 Nov 2020 - 2 Dec 2020
Organizer
Silver Level Support
Sponsor logos
Gilead logo

International Workshop on HBV Cure 2020

Related Enduring Materials

Enduring Materials
Pre AASLD Session - 11 November 2020 -
Potential of new combinations to achieve functional cure for Chronic Hepatitis B
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
Rationale for including immune tolerant and low viral load patients in new drug trials
Henry Lik Yuen Chan MD, FRCP (Edin, Lond), FAASLD
Henry Lik Yeun Chan, MBChB, MD, FRCP, FAASLD, FHKCP, FHKAM
The Chinese University of Hong Kong, Hong Kong, China
How to interpret flares in HBV trials with novel agents
Pietro Lampertico, MD, PhD
University of Milan, Italy
Toxicity in new and established HBV compounds
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada
Safety monitoring for different drug classes and antiviral discontinuation
Poonam Mishra, MD, MPH, FAASLD
US Food and Drug Administration, United States
Post AASLD Session - 02 December 2020 -
Update on new antiviral targets - Capsid Inhibitors
Kosh Agarwal, MD
King’s College Hospital, United Kingdom
Update on new antiviral targets - non-Capsid Inhibitors
Man-Fung Yuen, MBBS, MD, PhD, DSc
University of Hong Kong and Li Shu Fan Medical Foundation, Hong Kong
Update on new immuno modulators
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
Update on Hepatitis Delta therapy
Robert Gish MD, FAASLD
Robert Gish, MD, FAASLD
University of California - San Diego, San Diego, United States
Update on novel combination strategies
Marion Peters, MD
Northwestern University, United States
Overview
Welcome

Despite our best efforts to hold the International Workshop on HBV Cure as a live program, the Organizing Committee and Virology Education have concluded that it was best to hold the workshop virtually.

Fortunately, this provided new format opportunities and enabled us to offer the workshop in two parts. One took place before the AASLD Liver Meeting and one took take place afterwards to discuss the results.

Since 2014, the International Workshop on HBV Cure has been a scientific platform that acts as a catalyst to accelerate the progress for achieving a cure. Around the globe, more than 250 million people are chronically infected with hepatitis B (HBV). The purpose of the workshop is to inform the participants about the developments in the possibilities to find a cure for HBV. The meeting will be highly interactive with input from experts out of the arena of basic, translational, and clinical HBV research.

The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available are providing great hopes for decreasing the burden of the disease, simplifying treatment, and ultimately curing and eradicating HBV infection.

In order to optimize curative treatment for HBV, outstanding speakers from around the globe will share the newest therapeutic options for viral hepatitis, and experts will discuss the path forward to cure this deadly disease, leading to liver cirrhosis and liver cancer. Questions on which endpoints to use in therapeutic trials and how to combine different agents targeting the virus and/or immune system will be extensively discussed.

This workshop also brought together global inter-disciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.

Program Chairs 2020
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
COVID-19 Update
In light of the COVID-19 pandemic, the Organizing Committee of the International Workshop on HBV Cure 2020 reached the difficult decision to transform this year's event into a completely virtual meeting. In this way, the program was delivered safely and conveniently.

To deliver a highly educational, interactive, and enjoyable experience, it was decided to divide the program in two separate days: the first session took place on 11 November; the second session will take took place on 2 December. Ample time was reserved for discussion and virtual networking opportunities. We offered delegates a special reduced fee to participate in this online program.

We are available to answer any questions or concerns that you may have about your participation at the International Workshop on HBV Cure 2020. For more information, please contact Patrick Conings at patrick@amededu.com.

To stay updated on developments in relation to the International Workshop on HBV Cure, make sure you are signed up for our newsletter.
Unique Features
- Two-day virtual meeting

- Invited lectures from international experts

- Interactive roundtable discussions

- Ample time for discussion
Meeting Objectives
The objectives of this workshop are to:

- Discuss how to reach an HBV functional cure with newly developed agents targeting the immune system or the viral replication cycle;

- Develop endpoints and better biomarkers for these studies;

- Discuss how new agents should be combined to reach the goal of a functional cure.
Learning Objectives
After attending this workshop, participants will be able to:

- Critically evaluate biomarkers used in clinical HBV studies;

- Outline advances made to cure HBV;

- Critically assess current approaches taken to achieve the development of a functional cure.

Practical Information 

Certificate of Attendance
A certificate of attendance was sent to participants after they attended the conference and completed the post-meeting survey.
Language
The official language of the workshop was English.
Translation will not be provided.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Committees
Chairs 2020
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Organizing Committee
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Support
Endorsers
Language